NASDAQ:XOMAP XOMA (XOMAP) Stock Price, News & Analysis $25.45 -0.10 (-0.39%) Closing price 03:45 PM EasternExtended Trading$25.33 -0.12 (-0.47%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About XOMA Stock (NASDAQ:XOMAP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XOMA alerts:Sign Up Key Stats Today's Range$25.37▼$25.5550-Day Range$25.23▼$27.3652-Week Range$25.14▼$30.00Volume353 shsAverage Volume2,077 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield8.49%Price TargetN/AConsensus RatingN/A Company Overview XOMA Corporation (NASDAQ: XOMAP) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic antibodies for autoimmune and inflammatory diseases. The company leverages proprietary antibody-generation technologies—including ribosome display and phage display—to identify and optimize human monoclonal antibodies with high specificity and favorable pharmacological profiles. Its lead clinical program is an interleukin-1 beta modulator being evaluated in patients with rare and severe inflammatory conditions. In addition to its flagship candidate, XOMA is advancing earlier-stage antibody drug candidates targeting other immune pathways in preclinical development. These efforts aim to address both orphan and more prevalent indications, reflecting the company’s commitment to delivering innovative biologics to patients with unmet medical needs. Founded in 1981 and headquartered in Berkeley, California, XOMA has cultivated strategic collaborations with major pharmaceutical partners to co-develop and license antibody programs. The company’s operations extend primarily across the United States, with regulatory and clinical development activities also underway in Europe and other regions. XOMA is led by a management team with extensive experience in antibody drug discovery and clinical development.AI Generated. May Contain Errors. Read More Receive XOMAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XOMAP Stock News HeadlinesXOMA Co. (NASDAQ:XOMAP) Short Interest UpdateMay 31, 2026 | americanbankingnews.comXOMA Royalty Corp.May 26, 2026 | money.usnews.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.June 5 at 1:00 AM | Brownstone Research (Ad)Xoma AB Series BMay 25, 2026 | barrons.comXOMA royalty (XOMA) price target decreased by 32.32% to 45.39May 14, 2026 | msn.comHC Wainwright & Co. downgrades XOMA Royalty (XOMA)April 30, 2026 | msn.comLGND: XOMA Buy Adds 100+ AssetsApril 29, 2026 | finance.yahoo.comLigand to buy XOMA Royalty for $39/shareApril 27, 2026 | msn.comSee More Headlines XOMAP Stock Analysis - Frequently Asked Questions How have XOMAP shares performed this year? XOMA's stock was trading at $26.8690 at the start of the year. Since then, XOMAP shares have decreased by 5.3% and is now trading at $25.45. How do I buy shares of XOMA? Shares of XOMAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Record date for 4/15 Dividend4/02/2026Ex-Dividend for 4/15 Dividend4/02/2026Dividend Payable4/15/2026Today6/05/2026Next Earnings (Estimated)7/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2d) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 As of 2 days ago, XOMAP's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XOMAP CIK791908 Webwww.xoma.com Phone510-204-7200FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$7.65 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:XOMAP) was last updated on 6/5/2026 by MarketBeat.com Staff. From Our Partners$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
